Low density lipoprotein receptor-negative mice expressing human apolipoprotein B-100 develop complex atherosclerotic lesions on a chow diet: no accentuation by apolipoprotein(a).

We have generated mice with markedly elevated plasma levels of human low density lipoprotein (LDL) and reduced plasma levels of high density lipoprotein. These mice have no functional LDL receptors [LDLR-/-] and express a human apolipoprotein B-100 (apoB) transgene [Tg(apoB+/+)] with or without an apo(a) transgene [Tg(apoa+/-)]. Twenty animals (10 males and 10 females) of each of the following four genotypes were maintained on a chow diet: (i) LDLR-/-, (ii) LDLR-/-;Tg(apoa+/-), (iii) LDLR-/-;Tg(apoB+/+), and (iv)LDLR-/-;Tg(apoB+/+);Tg(apo+/-). The mice were killed at 6 mo, and the percent area of the aortic intimal surface that stained positive for neutral lipid was quantified. Mean percent areas of lipid staining were not significantly different between the LDLR-/- and LDLR-/-;Tg(apoa+/-) mice (1.0 +/- 0.2% vs. 1.4 +/- 0.3%). However, the LDLR-/-;Tg(apoB+/+) mice had approximately 15-fold greater mean lesion area than the LDLR-/- mice. No significant difference was found in percent lesion area in the LDLR-/-;Tg(apoB+/+) mice whether or not they expressed apo(a) [18.5 +/- 2.5%, without lipoprotein(a), Lp(a), vs. 16.0 +/- 1.7%, with Lp(a)]. Histochemical analyses of the sections from the proximal aorta of LDLR-/-;Tg(apoB+/+) mice revealed large, complex, lipid-laden atherosclerotic lesions that stained intensely with human apoB-100 antibodies. In mice expressing Lp(a), large amounts of apo(a) protein colocalized with apoB-100 in the lesions. We conclude that LDLR-/-; Tg(apoB+/+) mice exhibit accelerated atherosclerosis on a chow diet and thus provide an excellent animal model in which to study atherosclerosis. We found no evidence that apo(a) increased atherosclerosis in this animal model.

[1]  R. Hammer,et al.  Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. , 1993, The Journal of clinical investigation.

[2]  R. Krauss,et al.  Overexpression of human apolipoprotein B-100 in transgenic rabbits results in increased levels of LDL and decreased levels of HDL. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[3]  S. Young,et al.  Conservation of the Low Density Lipoprotein Receptor‐Binding Domain of Apoprotein B , 1986, Arteriosclerosis.

[4]  A. Lusis,et al.  Genetic control of inflammatory gene induction and NF-kappa B-like transcription factor activation in response to an atherogenic diet in mice. , 1993, The Journal of clinical investigation.

[5]  S. Young,et al.  Susceptibility to atherosclerosis in mice expressing exclusively apolipoprotein B48 or apolipoprotein B100. , 1997, The Journal of clinical investigation.

[6]  W. H. Hannon,et al.  International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material. , 1993 .

[7]  R. Lawn,et al.  Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice , 1994, Nature.

[8]  R. Hammer,et al.  Relative contributions of apolipoprotein(a) and apolipoprotein-B to the development of fatty lesions in the proximal aorta of mice. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[9]  E. Rubin,et al.  Feedback Mechanism of Focal Vascular Lesion Formation in Transgenic Apolipoprotein(a) Mice* , 1996, The Journal of Biological Chemistry.

[10]  E. Rubin,et al.  Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells , 1992, Cell.

[11]  R. Hammer,et al.  Atherogenesis in transgenic mice expressing human apolipoprotein(a) , 1992, Nature.

[12]  N. Maeda,et al.  Diet-induced atherosclerosis in mice heterozygous and homozygous for apolipoprotein E gene disruption. , 1994, The Journal of clinical investigation.

[13]  S. Ishibashi,et al.  Rapid genotyping of low density lipoprotein receptor knockout mice using a polymerase chain reaction technique , 1995, Laboratory animals.

[14]  S. Young,et al.  Transgenic mice expressing both human apolipoprotein B and human CETP have a lipoprotein cholesterol distribution similar to that of normolipidemic humans. , 1995, Journal of lipid research.

[15]  V. Armstrong,et al.  The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels. , 1986, Atherosclerosis.

[16]  M. Callow,et al.  Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a). , 1995, The Journal of clinical investigation.

[17]  R. Ross,et al.  ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[18]  M. Callow,et al.  Expression of human apolipoprotein B and assembly of lipoprotein(a) in transgenic mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[19]  E. Rubin,et al.  Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. , 1994, The Journal of clinical investigation.

[20]  E M Rubin,et al.  Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. , 1995, Journal of lipid research.

[21]  R. Hammer,et al.  Reconstitution of lipoprotein(a) by infusion of human low density lipoprotein into transgenic mice expressing human apolipoprotein(a). , 1992, The Journal of biological chemistry.

[22]  N. Maeda,et al.  Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[23]  D K Burns,et al.  Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. , 1994, The Journal of clinical investigation.

[24]  N. Maeda,et al.  Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. , 1992, Science.

[25]  J. Breslow,et al.  Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[26]  E. Rubin,et al.  Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice. , 1997, The Journal of clinical investigation.

[27]  Robert V Farese,et al.  Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet. , 1995, The Journal of clinical investigation.

[28]  E. Rubin,et al.  Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice. , 1994, Journal of lipid research.

[29]  F. James Rohlf,et al.  Biometry: The Principles and Practice of Statistics in Biological Research , 1969 .